FINNENCE ▪ THE WIRE FILE
THE WIRE · № 55476
Company■ Unclear/unknown
New Phase 3 trial: A Study to Assess the Efficacy and Safety of Afimkibart for Induction Therapy in Participants With Moderately to Severely Active Ulcerative Colitis — Hoffmann-La Roche
KINDCompany
DIRECTION■ Unclear/unknown
SOURCES1
ENTITIES1
STORY SIZESTANDALONE
FIRST SEEN2026-09-29 12:00 UTC
LAST UPDATE2026-09-29 12:00 UTC
STATEactive
01 THE MACHINE READ
WHY IT MATTERS.
A new Roche Phase 3 in ulcerative colitis is early-stage pipeline news with no near-term revenue impact.
Roche expands immunology pipeline
CATALYST TO WATCH
Interim trial data readouts
MAIN RISK
Not yet recruiting; long development timeline
FULL DISPATCH
Sponsor: Hoffmann-La Roche; Status: Not Yet Recruiting; Conditions: Moderately to Severely Active Ulcerative Colitis; Interventions: Afimkibart, Placebo; Enrollment: 350 (estimated); First posted: 2026-09-29; NCT: NCT07846683
02 THE STORY SO FAR
THE RECORD, IN ORDER.
STANDALONE ITEM — NOT YET FOLDED INTO A DEVELOPING STORY.
03 WHO'S INVOLVED
ENTITIES ON FILE.
AFFECTEDHealthcare
04 RECEIPTS
THE SOURCE RECORD.
1 SOURCES CONFIRMED05 PROPAGATION
WHAT THIS TOUCHES.
→CORRELATIONshares Healthcare
Phase 3 results posted: A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer — Seagen Inc.2026-09-29 12:00 UTC
Phase 3 results posted: A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer — Seagen Inc.2026-09-29 12:00 UTC
→CORRELATIONshares Healthcare
Phase 3 results posted: Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Negative Symptoms of Schizophrenia — Otsuka Pharmaceutical Development & Commercialization, Inc.2026-09-29 12:00 UTC
Phase 3 results posted: Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Negative Symptoms of Schizophrenia — Otsuka Pharmaceutical Development & Commercialization, Inc.2026-09-29 12:00 UTC
→CORRELATIONshares Healthcare
Phase 3 results posted: A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ≥60 Years of Age — ModernaTX, Inc.2026-09-29 12:00 UTC
Phase 3 results posted: A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ≥60 Years of Age — ModernaTX, Inc.2026-09-29 12:00 UTC
→CORRELATIONshares Healthcare
Another proposed mega merger: HealthPartners, Essentia Health boards approve plan to combine organizations2026-09-29 15:50 UTC
Another proposed mega merger: HealthPartners, Essentia Health boards approve plan to combine organizations2026-09-29 15:50 UTC
→CORRELATIONshares Healthcare
Health tech's dealmaking boom is back as firms chase scale and profitable growth2026-09-29 16:00 UTC
Health tech's dealmaking boom is back as firms chase scale and profitable growth2026-09-29 16:00 UTC
→CORRELATIONshares Healthcare
Minnesota health systems HealthPartners, Essentia Health announce plan to merge2026-09-29 16:11 UTC
Minnesota health systems HealthPartners, Essentia Health announce plan to merge2026-09-29 16:11 UTC
KEEP READING THE MACHINE
Summaries are generated and may contain errors — every claim links its sources.